Drugs / BDC-4182
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06921837 | May 2025 → May 2027 expected | gastric adenocarcinoma, gastroesophageal adenocarcinoma | Bolt Biotherapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-01 | Bolt Biotherapeutics, Inc. | Results Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 boltbio.com ↗
A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. |
| 2024-11-07 | Bolt Biotherapeutics, Inc. | Results Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting boltbio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-01 | Bolt Biotherapeutics, Inc. | Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 boltbio.com ↗ |
| 2024-11-07 | Bolt Biotherapeutics, Inc. | Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting boltbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BDC-4182 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06921837 ↗ |
| Action | Activate | “TLR 7/8 dual agonist” NCT06921837 ↗ |
| Modality | Monoclonal antibody | “anti-claudin 18.2 monoclonal antibody” NCT06921837 ↗ |